Goldman Sachs Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $140
BTIG Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $150
Morgan Stanley Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $132
Natera Analyst Ratings
Piper Sandler Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $150
TD Cowen Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $145
Strong Buy Rating for Natera's MRD Testing Backed by Promising Clinical Data and Potential for Improved Survival Outcomes
TD Cowen Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $145
CCORF Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $145
Craig-Hallum Maintains Natera(NTRA.US) With Buy Rating
Natera Analyst Ratings
CCORF Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $145
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Natera (NTRA) and Disc Medicine (IRON)
Morgan Stanley Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $132
J.P. Morgan Sticks to Their Buy Rating for Natera (NTRA)
Piper Sandler Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $150
Natera Analyst Ratings
Natera Price Target Maintained With a $125.00/Share by Stephens & Co.
UBS Cuts Price Target on Natera to $145 From $160, Maintains Buy Rating
Natera Inc. (NTRA) Exceeds Q2 Expectations With Strong Growth and Upward Guidance, Securing a Buy Rating